A New Jersey-based biotech company is turning heads on Tuesday after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201.

To read the full story on AllPennyStocks.com, click here.

VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more VYNE Therapeutics Charts.
VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more VYNE Therapeutics Charts.